carbapenem

Meropenem (SM 7338) is a broad-spectrum carbapenem antibiotic administered intravenously for severe bacterial infections caused by sensitive agents. It commonly causes mild, transient aminotransferase elevations and can rarely lead to clinically apparent cholestatic liver injury.

Meropenem trihydrate (SM 7338 trihydrate) is a carbapenem antibiotic with broad-spectrum antibacterial activity.

Lenapenem is a broad-spectrum, carbapenem antibiotic with bactericidal activity by weakens the bacterial cell wall and leads to lytic cell death.

Ceftolozane sulfate (FR-264205) is a cephalosporin antibiotic with broad-spectrum antimicrobial activity, inhibits P. aeruginosa PAO1, inhibits Pseudomonas aeruginosa, and is used in the study of pneumonia.

WCK-4234 sodium (WCK 4234) is an inhibitor of β-lactamase can be used in studies targeting MDR infections. WCK-4234 sodium inhibits class A, C, and D β-lactamases and OXA carbapenemases.

Vaborbactam ammonium salt is a β-lactamase inhibitor that restores carbapenem activity against KPC-producing strains and is often used in conjunction with other drugs to study fungal infections.

Imipenem (MK0787) is a thienomycin derivative that belongs to the class of antibiotics with antibacterial activity and partial inhibition against gram-positive and gram-negative bacteria. Imipenem can be used to study carbapenem non-susceptible infections and Pseudomonas aeruginosa biofilm infections.

Imipenem monohydrate (Imipenem) is a carbapenem antibiotic isolated from the microorganism Streptomyces cattleya, and is a β lactam antibiotic. Imipenem monohydrate acts on the bacterial cell wall, and is a broadly effective inhibitor of a wide range of Gram-positive and negative bacteria.

ADC-13 ((5R,6S)-4-Nitrobenzyl 6-((R)-1-hydroxyethyl)-3,7-dioxo-1-azabicyclo[3.2.0]heptane-2-carboxylate) is a p-nitrobenzyl ester β-lactam derivative, functioning as an intermediate in carbapenem antibiotic synthesis.

Tebipenem is an orally available carbapenem antibiotic with broad-spectrum activity against both Gram-positive and Gram-negative bacteria.

Meropenem (SM 7338) sodium is a broad-spectrum carbapenem antibiotic that exhibits activity against both susceptible and resistant strains of Neisseria gonorrhoeae (MIC values of 0.02-0.06 mg/mL), Haemophilus influenzae (MIC values of 0.03-0.12 mg/mL), and Moraxella catarrhalis (MIC values of 0.015-0.12 mg/mL).

Ertapenem is a parenteral carbapenem. It has a broad spectrum of antimicrobial activity. It is highly resistant to inactivation by a wide variety of beta-lactamases.

Benapenem is a carbapenem (β-lactam) compound known for its broad-spectrum antibacterial activity. It is currently under clinical evaluation as an intravenous treatment option for urinary tract infections.

LYS228 (also known as Ancremonam) is a potent antibiotic effective against carbapenem-resistant Enterobacteriaceae bacteria (MIC90 = 2 uM/mL). It demonstrates strong antibacterial activity against CRE isolates even in the presence of all classes of β-lactamases.

KPC-IN-1 (compound 1e) is an inhibitor of Klebsiella pneumoniae carbapenemase KPC-2, with an IC50 value of 8.3 nM. KPC is a β-lactamase expressed in Gram-negative bacteria that hydrolyzes carbapenems, leading to significant bacterial resistance to carbapenem antibiotics.

Plazomicin (ACHN 490) sulfate is a potent aminoglycoside antibiotic that combats antibiotic resistance. It exhibits in vitro activity against various multidrug-resistant bacteria, including carbapenem-resistant Enterobacteriaceae. Plazomicin sulfate is utilized for treating multidrug-resistant complicated urinary tract infections (cUTIs) and is studied for use in severe carbapenem-resistant Enterobacteriaceae infections.

MBL-IN-5 is an inhibitor of metallo-β-lactamase (MBL). It effectively suppresses three clinically significant B1 subfamily MBLs: NDM-1, VIM-1, and IMP-1 with IC50 values of 0.05 nM, 14 nM, and 21 nM respectively. MBL-IN-5 notably enhances the efficacy of carbapenem antibiotics against MBL-producing clinical strains and, when combined with IPM antibiotics, significantly reduces bacterial load in a thigh infection model.

Panipenem is a carbapenem antibiotic used in combination with betamipron.

Antibacterialagent 285 (Compound 3) is a cephalosporin antibiotic. It exhibits significant antibacterial activity against Gram-negative bacteria, with minimum inhibitory concentrations (MIC) of 0.125-0.5 μg/mL for carbapenem-resistant Acinetobacter baumannii (CRAB), 0.125-0.5 μg/mL for Klebsiella pneumoniae (CRE), and 0.125-2 μg/mL for Pseudomonas aeruginosa (CRPA). Antibacterialagent 285 can be utilized in bacterial infection research, including studies on complicated urinary tract infections (cUTI) and kidney infections.

ZN148 is a synthetic chelatable zinc metallo-β-lactamase (MBL) inhibitor that can reduce carbapenem resistance mediated by MBLs. It is capable of restoring the in vitro clinical sensitivity to carbapenems in over 98% of strains in an internationally large MBL-producing clinical Enterobacteriaceae strain collection. ZN148 is applicable for research on MBL-producing bacteria.

KPC-2-IN-3 (Compound 3b) is a KPC-2 inhibitor with an IC50 of 0.533 μM and a Ki of 0.194 μM. It works synergistically with Meropenem to exhibit antibacterial activity against carbapenem-resistant K. pneumoniae K47-25, reducing bacterial count and demonstrating a post-antibiotic effect. Additionally, KPC-2-IN-3 significantly decreases lung bacterial load in a mouse pneumonia model.

ANT3310 is a broad-spectrum covalent inhibitor of serine β-lactamase (Serine β-Lactamase) with an IC50 range of 1 nM to 175 nM against various serine β-lactamases. ANT3310 enhances the efficacy of β-lactam antibiotics against carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Acinetobacter baumannii (CRAB). It is applicable for studies related to bacterial infections.

Doripenem is a new parenteral carbapenem antibiotic with broad-spectrum activity against gram-negative and gram-positive pathogens.

DA 1131 is a new carbapenem antibiotic. It undergoes renal metabolism by renal dehydropeptidase I.